Major US health insurer publishes positive coverage
Released
Released
Announcement PDF
Page | 1
ImpediMed Limited
Unit 31C, 12-18 Tryon Road
Lindfield
NSW 2070
Australia
E: investorrelations@impedimed.com
W: impedimed.com
2 October 2025
Companies Announcements Office
Australian Securities Exchange
Major US health insurer publishes positive coverage for BIS Lymphedema Assessment
ImpediMed Limited (ASX: IPD) (ImpediMed or the Company) is pleased to announce one of the
largest health insurers in the United States has issued positive coverage for CPT Code 93702,
recognising bioimpedance spectroscopy (BIS) as medically necessary for the assessment of
lymphedema. This decision supports reimbursement for lymphedema testing using ImpediMed’s
SOZO®
Digital Health Platform and represents a significant step forward in our mission to prevent
breast cancer-related lymphedema.
As the largest customer-owned insurer in the United States, and licensee of Blue Cross Blue Shield
Association in 5 states, they provide access to care nationwide through plans in Illinois, Montana,
New Mexico, Oklahoma and Texas. They rank as the fifth largest health insurance provider in the
United States with a stated mission of expanding access to high-quality care for their members.
This is a positive development for breast cancer survivors across the United States. These additional
insurance coverage for lymphedema assessment using bioimpedance spectroscopy (BIS), means
more than 86% of all US patients are now reimbursed for their treatment. This expanded access
means that millions of patients can benefit from earlier detection and more accurate monitoring of
lymphedema—one of the most common and debilitating side effects following breast cancer
treatment. Early identification through BIS allows for timely intervention, helping to prevent
progression to more severe stages of lymphedema, reduce long-term complications, and improve
overall quality of life. For survivors, this coverage expansion represents not just broader access to
care, but a meaningful step toward proactive, preventative health management and peace of mind
during recovery.
The announcement adds to the recent momentum in insurance coverage, representing an additional
sixteen million covered lives and bringing total reimbursed coverage for lymphedema testing using
ImpediMed’s SOZO® Digital Health Platform SOZO to over 301 million covered lives and 86%
coverage nationwide. Importantly it takes another 5 states above 80% coverage with 3 of those over
90%. Included in the five states are 2 of the 5 largest population States in the US in Texas and
Illinois. We expect these changes, together with those announced in the Q4 FY25 Quarterly Results,
to have a meaningful effect for commercialisation of SOZO.
Dr Parmjot Bains Managing Director of ImpediMed commented “During my US travels, I consistently
meet dedicated clinicians who are eager to integrate SOZO into their patient care pathways. In
today’s financially constrained healthcare environment, hospitals face a difficult balancing act—
managing tight budgets while striving to deliver the best possible clinical outcomes. Decisions from
major insurance companies to recognise the medical necessity of using bioimpedance spectroscopy
(BIS) for lymphedema assessment are pivotal. These greatly enhance the commercial feasibility of
Page | 2
implementing a SOZO-based lymphedema prevention program across many hospital systems and
progress toward our goal: ensuring every cancer patient at risk of lymphedema has access to
prospective surveillance through SOZO.”
Approved for release by the CEO and MD of ImpediMed Limited.
For more information, contact ImpediMed Investor Relations at investorrelations@impedimed.com.
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is
a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate
powerful data to maximise patient health. ImpediMed produces the SOZO®
Digital Health Platform,
which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including
lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.
In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®
) for
Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool
to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health
Platform and L-Dex®
, ImpediMed is the only company to offer FDA-cleared technology that uses
bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital
health platform and large, attractive cancer-related lymphoedema market present an opportunity for
continued strong growth through ImpediMed’s SaaS subscription-based business.
For more information, visit www.impedimed.com.
Forward looking statements
This announcement contains or may contain forward-looking statements that are based on
ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on
information currently available to management.
All statements that address operating performance, events or developments that we expect or
anticipate will occur in the future are forward-looking statements, including without limitation our
expectations with respect to our ability to expand sales and market acceptance in the US and
Australia including our estimates of potential revenues, costs, profitability and financial performance;
our ability to develop and commercialise new products including our ability to obtain reimbursement
for our products; our expectations with respect to our clinical trials, including enrolment in or
completion of our clinical trials and our associated regulatory submissions and approvals; our
expectations with respect to the integrity or capabilities of our intellectual property position. Any
forward-looking statements, including projections, guidance on future revenues, earnings and
estimates, are provided as a general guide only and should not be relied upon as an indication or
guarantee of future performance.
While management has prepared this information based on its current knowledge and understanding
and in good faith, there are risks and uncertainties involved which could cause actual results to differ
from projections. You should not place undue reliance on forward-looking statements which speak
only as of the date when made. Except as required by law, ImpediMed does not assume any
obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. ImpediMed may not actually achieve the plans, projections
or expectations disclosed in forward-looking statements. Actual results, developments or events
could differ materially from those disclosed in the forward-looking statements and no representation,
warranty or assurance (express or implied) is given or made in relation to any forward-looking
statement by any person (including ImpediMed Limited).
Share your feedback
Discover